Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01598 ...
Drug Name Imipenem
Molecular Weight 299.346
Molecular Formula C12H17N3O4S
CAS Number 64221-86-9
SMILES [H][C@]12CC(SCC\N=C\N)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O
External Links
DRUGBANK DB01598
T3DB T3D4739
PubChem Compound 104838

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Water Solubility 10000.0 mg/L 10000 mg/L MERCK INDEX 1996)
pKa 3.2 - 3.2 - MERCK INDEX (1996)

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 89.0 % 89 % IM,intramuscular injection; DRUGBANK
C Max 10100.0 ng/ml 8.2-12 mcg/ml IM,intramuscular injection; The Pharmacological Basis of Therapeutics
C Max 65000.0 ng/ml 60-70 mcg/ml intravenous infusion, IV in drop; The Pharmacological Basis of Therapeutics
T Max 1.5 h 1-2 h IM,intramuscular injection; The Pharmacological Basis of Therapeutics
Clearance 0.21 L/h/kg 0.2 l/h/kg Total clearance; DRUGBANK
Clearance 0.0500 L/h/kg 0.05 l/h/kg Renal clearance; Single dose; DRUGBANK
Clearance 0.15 L/h/kg 0.15 l/h/kg Renal clearance; Drug combination; DRUGBANK
Clearance 0.17 L/h/kg 2.9 ml/min/kg Neonates → ;Children ↑ ;Elderly → ;Prem, premature → ;RD, renal impairment, Renal disease，including uremia ↓ ;Cystic fibrosis → ;inflammation → ;Burn → ; The Pharmacological Basis of Therapeutics
Clearance 0.18 L/h/kg 3.0±0.3 ml/min/kg Neonates ↓ ;Children ↑ ;Prem, premature ↓ ;Elderly → ;RD, renal impairment, Renal disease，including uremia ↓ ;Cystic fibrosis → ; The Pharmacological Basis of Therapeutics
Clearance 0.18 L/h/kg 3 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 0.27 L/kg 0.23-0.31 L/kg DRUGBANK
Volume of Distribution 0.23 L/kg 0.23±0.05 L/kg Neonates ↑ ;Children ↑ ;Prem, premature ↑ ;Elderly → ;RD, renal impairment, Renal disease，including uremia → ;Cystic fibrosis → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.20 L/kg 0.20±0.03 L/kg Neonates → ;Elderly → ;Prem, premature ↑ ;RD, renal impairment, Renal disease，including uremia → ;Cystic fibrosis → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.24 L/kg 0.24 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 1.0 h 1 h intravenous injection, IV; DRUGBANK
Half-life 3.2 h 1.3-5.1 h IM,intramuscular injection; DRUGBANK
Half-life 0.90 h 0.9±0.1 h Neonates ↑ ;Prem, premature ↑ ;Children → ;RD, renal impairment, Renal disease，including uremia ↑ ;Cystic fibrosis → ;Age → ; The Pharmacological Basis of Therapeutics
Half-life 0.80 h 0.8±0.1 h Neonates ↑ ;Prem, premature ↑ ;Cystic fibrosis → ;Age → ; The Pharmacological Basis of Therapeutics
Half-life 0.95 h 0.95 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Eliminate Route 69.0 % 69±15 % Urinary excretion; Drug combination; Unchanged drug; Neonates ↓ ;Children → ;inflammation ↓ ;Cystic fibrosis → ; The Pharmacological Basis of Therapeutics
Eliminate Route 70.0 % 70±3 % Urinary excretion; Drug combination; Unchanged drug; Neonates ↓ ;Cystic fibrosis → ; The Pharmacological Basis of Therapeutics
Protein Binding 20.0 % 20 % plasma proteins; DRUGBANK
Protein Binding 20.0 % <20 % Drug combination; The Pharmacological Basis of Therapeutics
Protein Binding 35.0 % ~35 % Drug combination; The Pharmacological Basis of Therapeutics

Maximum Dosage

Not Available

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1